![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of Optogenetics-based AAV gene therapy as the basis of successful therapeutics.
Lead Product(s): Optogenetics-based AAV Gene Therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2021